For the double-blind portion of the study, dosing will be initiated in a subgroup of adults who are 18-65 years of age. Following independent Data Monitoring Board review of subgroup safety data, and review and confirmation to proceed by FDA, enrollment of subjects <18 years of age will commence.
This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects with PWS.